Here is a comprehensive overview of heart failure:
Heart Failure
Definition
Heart failure (HF) is a clinical syndrome in which the heart is unable to pump sufficient blood to meet the body's metabolic demands, or can only do so at elevated filling pressures. It is characterized by symptoms (dyspnea, fatigue, fluid retention) resulting from structural or functional cardiac abnormality.
Classification by Ejection Fraction
The most clinically important classification is based on Left Ventricular Ejection Fraction (LVEF), as it guides therapy:
| Type | Abbreviation | LVEF | Description |
|---|
| HF with Reduced EF | HFrEF | < 40% | Systolic dysfunction; impaired contractility |
| HF with Mildly Reduced EF | HFmrEF | 40–49% | Intermediate group; may represent improving HFrEF or worsening HFpEF |
| HF with Preserved EF | HFpEF | ≥ 50% | Diastolic dysfunction; impaired relaxation/filling |
Per the Universal Definition of HF and U.S. Heart Failure Collaboratory consensus, HFpEF is defined as a clinical diagnosis of HF with LVEF ≥50%. HFmrEF provides a distinct category for individuals with stable preserved EF where measurement variability may exist (Management of Heart Failure With Preserved Ejection Fraction, p. 3).
Other Classification Systems
By Onset
- Acute HF — Rapid onset, often requiring hospitalization (e.g., acute pulmonary edema, cardiogenic shock)
- Chronic HF — Gradual, longstanding; may decompensate acutely
By Side
- Left-sided HF — Pulmonary congestion, dyspnea, orthopnea, paroxysmal nocturnal dyspnea
- Right-sided HF — Systemic venous congestion, peripheral edema, ascites, JVD
- Biventricular HF — Both ventricles affected
By Output
- Low-output HF — Most common; reduced cardiac output (ischemic, dilated cardiomyopathy)
- High-output HF — Normal/elevated CO but still insufficient (e.g., severe anemia, thyrotoxicosis, AV fistula)
NYHA Functional Classification
| Class | Description |
|---|
| I | No symptoms with ordinary activity |
| II | Mild symptoms; slight limitation |
| III | Marked limitation; comfortable only at rest |
| IV | Symptoms at rest; unable to carry any activity |
Common Etiologies
- Coronary artery disease / MI (most common in developed countries)
- Hypertension
- Dilated, hypertrophic, or restrictive cardiomyopathy
- Valvular heart disease
- Arrhythmias (e.g., AF)
- Myocarditis
- Diabetes mellitus
- Congenital heart disease
Treatment
HFrEF (LVEF < 40%) — Pharmacotherapy
The 2021 ESC Guidelines recommend quadruple therapy as the cornerstone of HFrEF treatment, initiated early and up-titrated rapidly (Management of Cardiovascular Disease in Patients with Diabetes, p. 46):
| Drug Class | Examples | Key Benefit |
|---|
| ARNI (preferred) or ACE-I/ARB | Sacubitril/valsartan; Enalapril; Losartan | Reduce preload/afterload, neurohormonal blockade |
| Beta-blocker | Carvedilol, Metoprolol succinate, Bisoprolol | Reduce HR, reverse remodeling |
| MRA (Mineralocorticoid receptor antagonist) | Spironolactone, Eplerenone | Reduce fibrosis, diuresis |
| SGLT2 inhibitor | Dapagliflozin, Empagliflozin | Reduce HF hospitalization and CV death |
The STRONG-HF trial demonstrated that early, intensive up-titration to target doses within 2 weeks of discharge reduced 180-day HF rehospitalization or all-cause death by 34% (HR 0.66; 95% CI 0.50–0.86).
Additional agents:
- Loop diuretics (e.g., furosemide) — for congestion/volume overload relief
- Ivabradine — if HR ≥70 bpm on maximum beta-blocker
- Hydralazine + nitrate — if ACE-I/ARB/ARNI not tolerated (especially in Black patients)
- Digoxin — for symptom control in select cases
HFpEF (LVEF ≥ 50%) — Management
HFpEF has fewer proven disease-modifying therapies, but management includes:
- SGLT2 inhibitors (Dapagliflozin/Empagliflozin) — now recommended; reduce HF hospitalizations
- Diuretics — for symptomatic congestion
- Control of underlying causes: hypertension, AF, obesity, diabetes
- MRAs (spironolactone) — modest benefit in some patients
- Emerging: GLP-1 receptor agonists in obese HFpEF
Device Therapy
| Device | Indication |
|---|
| ICD (Implantable Cardioverter-Defibrillator) | LVEF ≤35%, NYHA II–III, on optimal medical therapy |
| CRT (Cardiac Resynchronization Therapy) | LVEF ≤35% + LBBB + QRS ≥150 ms |
| LVAD (Left Ventricular Assist Device) | Advanced HF; bridge to transplant or destination therapy |
| Heart transplantation | End-stage HF refractory to all therapy |
Non-Pharmacological Measures
- Sodium and fluid restriction
- Daily weight monitoring
- Cardiac rehabilitation and exercise training
- Smoking cessation, alcohol limitation
- Multidisciplinary HF clinic follow-up
Key Takeaway
Heart failure management is ejection-fraction driven. HFrEF has robust evidence for quadruple pharmacotherapy (ARNI/ACE-I + beta-blocker + MRA + SGLT2i). HFpEF management primarily targets symptoms and underlying comorbidities, with SGLT2 inhibitors being the most recent evidence-based addition across both phenotypes.